FDA clears Elevar's bile duct cancer drug as second-line therapy
The FDA approved Elevar Therapeutics' Lyrfigtu for certain patients with bile duct cancer as a second-line treatment. The decision was based on clinical trial results. Bile duct cancer is diagnosed in about 8,000 Americans each year.
The approval gives oncologists a new tool for patients whose bile duct cancer has advanced despite initial therapy. Second-line options are critical in this disease, as tumors frequently become resistant to frontline regimens. The regulatory decision was supported by clinical trial evidence demonstrating benefit in the targeted patient population.
Bile duct cancer remains relatively uncommon, with roughly 8,000 new diagnoses in the U.S. each year, yet it carries a poor prognosis and limited treatment pathways. Expanding the arsenal beyond first-line care addresses a real gap for these patients, many of whom face few alternatives once standard treatment stops working.
This approval could meaningfully broaden options for a patient group with historically scarce choices after initial treatment fails. For the approximately 8,000 Americans diagnosed annually, a new second-line therapy may extend survival or improve quality of life in some cases. It may also signal renewed momentum in rare-cancer drug development, potentially encouraging further investment in biliary tract research. Real-world impact, however, will depend on how the drug performs across broader, more diverse patient populations than those in clinical trials.